Cardiac xenotransplantation: Recent preclinical progress with 3-month median survival

ObjectivesTransplantation is limited by a lack of human organ donors. Organs derived from animals, most likely the pig, represent a potential solution to this problem. For the heart, 90-day median graft survival of life-supporting pig hearts transplanted to nonhuman primates has been considered a reasonable standard for entry into the clinical arena. Overcoming the immune barrier to successful cardiac xenotransplantation is most appropriately first explored with the non–life-supporting heterotopic model.MethodsWe performed a series of 7 heterotopic heart transplantations from CD46 transgenic pigs to baboons using a combination of therapeutic agents largely targeted at controlling the synthesis of anti-pig antibodies. Rituximab (anti-CD20) and Thymoglobulin (rabbit antithymocyte globulin [ATG]; SangStat Medical Corp, Fremont, Calif) were used as induction therapy. Baseline immunosuppression consisted of splenectomy, tacrolimus, sirolimus, steroids, and TPC (an anti-Gal antibody therapeutic). Rejection events were not treated.ResultsBy using Kaplan-Meier analysis, median graft survival was 96 days (range, 15–137 days; 95% confidence interval, 38–99 days). Only 2 grafts were lost as a result of rejection, as defined by cessation of graft palpation. There was no evidence of a consumptive coagulopathy, infectious complications were treatable, and no posttransplantation lymphoproliferative disorders occurred. No cellular infiltration was observed.ConclusionsThis study reports the longest median survival to date (96 days) of pig hearts transplanted heterotopically into baboons. Duplication of these results in the orthotopic life-supporting position could bring cardiac xenotransplantation to the threshold of clinical application

Patient Self-reported Breast Cup Size and Resultant Mastectomy Specimen Weight: Implications for Reconstructive Breast Surgery

Background:. Breast cup sizing irregularities exist due to discrepancy between garment manufacturers and patient reported measurements making it difficult to assess true preoperative and definitive postoperative breast cup size. This study aims to evaluate the association between patient self-reported breast cup size and mastectomy specimen weight as a way to determine postreconstruction breast cup size. Methods:. This is a retrospective study that evaluated patients who underwent bilateral mastectomy at an academic center between 2019–2021. Cup size and mastectomy weight were our only independent and dependent variables, respectively. Covariates that were assessed included chest circumference, surgical oncologist, BMI, race, and age. Results:. 243 patients were evaluated as a part of this study who underwent either total-simple (TS; 29), skin-sparing (SS; 146), or nipple-sparing (NS; 68) bilateral mastectomy. There were positively weak correlations using nonparametric correlation analysis for breast cup size to mastectomy weight in patients who underwent TS (r = 0.375; p = 0.004), SS (r = 0.353; p <0.001), and NS (r = 0.246; p = 0.004) mastectomy. The multivariate linear regression for TS (R2=0.520; p < 0.001), SS (R2=0.573; p < 0.001) and NS (R2=0.396; p < 0.001) mastectomy were significant. Covariates assessed in the regression showed BMI significant for all types, age for TS type, and SS type for breast surgeon and chest circumference. Conclusions:. There is a positively weak correlation between preoperative breast cup size and mastectomy weight, providing evidence for the difficulty of estimating postoperative breast cup size. Thus, the conversation with the patient should focus on breast appearance and quality of life rather than postreconstruction breast size